Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
7.07
-0.56 (-7.34%)
At close: Mar 3, 2026, 4:00 PM EST
7.30
+0.23 (3.25%)
After-hours: Mar 3, 2026, 4:17 PM EST
Alpha Tau Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Alpha Tau Medical stock have an average target of 9.50, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 34.37% from the current stock price of 7.07.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alpha Tau Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +69.73% | Feb 24, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | -0.99% | Dec 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +27.30% | Nov 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +27.30% | Oct 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +27.30% | Sep 3, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.63M
EPS This Year
-0.52
from -0.45
EPS Next Year
-0.49
from -0.52
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 3.4M | ||||
| Avg | n/a | 1.6M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.51 | -0.47 | ||||
| Avg | -0.52 | -0.49 | ||||
| Low | -0.53 | -0.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.